Form 8-K - Current report:
SEC Accession No. 0001787306-25-000004
Filing Date
2025-01-13
Accepted
2025-01-13 07:33:31
Documents
15
Period of Report
2025-01-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arqt-20250112.htm   iXBRL 8-K 28505
2 EX-99.1 pressreleaseex991pre-earni.htm EX-99.1 17940
6 a1a82a.jpg GRAPHIC 25530
  Complete submission text file 0001787306-25-000004.txt   213460

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arqt-20250112.xsd EX-101.SCH 1770
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT arqt-20250112_lab.xml EX-101.LAB 22804
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT arqt-20250112_pre.xml EX-101.PRE 13038
17 EXTRACTED XBRL INSTANCE DOCUMENT arqt-20250112_htm.xml XML 2864
Mailing Address 3027 TOWNSGATE ROAD SUITE 300 WESTLAKE VILLAGE CA 91361
Business Address 3027 TOWNSGATE ROAD SUITE 300 WESTLAKE VILLAGE CA 91361 805-418-5006
Arcutis Biotherapeutics, Inc. (Filer) CIK: 0001787306 (see all company filings)

EIN.: 812974255 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39186 | Film No.: 25524816
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)